Targeting Neurotransmitters for the Management of Insomnia
neuroscienceCME Clinical NavigatorPremiere Date: Friday, October 17, 2014
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, October 17, 2015
Note: Credit Is No Longer Available
|Andrew D. Krystal, MD, MS
Professor of Psychiatry and Behavioral Sciences
Duke University School of Medicine
|Karl Doghramji, MD
Professor of Psychiatry
Jefferson Medical College
Director, Sleep Disorders Center
Thomas Jefferson University Hospital
|Thomas Roth, PhD
Chief, Division Head
Sleep Disorders and Research Center
Henry Ford Hospital
|Thomas E. Scammell, MD
Professor of Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children's Hospital
Insomnia can affect many aspects of an individual’s life: impairing concentration and memory, increasing the risk of incident depression or recurrence of a depressive episode, diminishing a patient’s ability to enjoy family and social relationships, and increasing the risks of falls and motor vehicle accidents.
This neuroscienceCME Clinical Navigator is the second supplement in a two-part series derived from an Expert Roundtable. Following up on the May 2014 Psychiatric News supplement titled, “New Insights Into Sleep-Wake System Neurobiology and Pathophysiology of Insomnia1,” it will describe the treatments used in insomnia, so that clinicians understand more about the roles of neurotransmitters and therapeutic agents, including orexin antagonists. It is important for clinicians to be aware of emerging agents in order to tailor treatments to individual needs as new therapeutic options for insomnia become available.
- Krystal AD, Doghramji K, Roth T, Scammel T. New Insights Into the Sleep-Wake System: The Neurobiology and Pathophysiology of Insomnia. Psychiatr News. May 16, 2014;49(10)(Suppl).
This educational activity centers on the CME Outfitters Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants.
The Make One Change Statement for this activity is: Psychiatrists will stay abreast of emerging research findings and describe the treatments for insomnia.
At the end of this CE activity, participants should be able to:
- Evaluate how research findings for emerging agents will likely affect routine clinical practice in the care of patients with insomnia.
Supported by an independent educational grant from Merck & Co., Inc.
Psychiatrists and other health care professionals interested in sleep-wake medicine
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Krystal has disclosed that he has received grant support from Astellas Pharma Inc.; Janssen Pharmaceuticals, Inc.; Novartis Corporation; Sunovion Pharmaceuticals Inc.; and Teva Pharmaceuticals USA. He serves as a consultant to AstraZeneca; Eisai Inc.; Jazz Pharmaceuticals, Inc; Johnson and Johnson; Merck & Co; Roche; Somnus Therapeutics Inc; Teva Pharmaceuticals USA; and Vantia Ltd.
Dr. Doghramji has disclosed that he serves as a consultant to Aptalis; Jazz Pharmaceuticals, Inc.; and Vanda Pharmaceuticals. He is a stock shareholder in Merck & Co., Inc.
Dr. Roth has disclosed that he has received grant support from Cereve; and Proctor and Gamble. He serves as a consultant to Aptalis; Cereve; Intec Pharma ltd.; Jazz Pharmaceuticals, Inc.; Merck & Co; Novartis Corporation; Shire Pharmaceuticals Inc.; Sunovian Pharmaceuticals Inc.; and Teva Pharmaceuticals USA. Inc. He is on the speakers bureau of Purdue Pharma L.P.
Dr. Scammel has disclosed that he has received grant support from Eisai Co., Ltd. He serves as a consultant for Cereve; Ferrer; Jazz Pharmaceuticals Inc.; Merck & Co., Inc.; and Purdue Pharma L.P.
Tony Graham, MD (peer review) has no disclosures to report.
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose.
Unlabeled Use Disclosure
Faculty of this CME activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).